Turinabol (4-Chlorodehydromethyltestosterone) Research Hub | QSC Peptides
QSC RESEARCH HUB — ORAL ANABOLIC STEROID
Turinabol (4-Chlorodehydromethyltestosterone)17α-methyl-4-chloro-testosterone derivative — state-doping era compoundA:A 100-200:50Research Use Only
Compound Specification
Property
Value
Compound
Turinabol (4-Chlorodehydromethyltestosterone)
CAS
2446-23-3
MW
334.87 g/mol
Class
17α-methyl-4-chloro-testosterone derivative — state-doping era compound
Anabolic:Androgenic ratio
100-200:50
Aromatisation
No — 4-chloro substitution prevents aromatisation
Route
Oral — 17α-alkylated (hepatotoxic at high dose/long duration)
QSC format
Research tablet kits ≥99% HPLC — Janoshik COA
Mechanism of Action
Turinabol (4-chloro-17α-methyl-androst-1,4-dien-17β-ol-3-one) is a Dianabol derivative with a 4-chloro substitution that blocks aromatisation via CYP19A1. The 4-chloro group prevents the aromatase enzyme from accessing the substrate, making turinabol non-oestrogenic despite its testosterone structural similarity. Historically significant: turinabol was synthesised in East Germany in 1962 and used systematically in the GDR state doping programme — making it the most extensively documented state-administered oral anabolic steroid. Research value: the 4-chloro modification and its effect on CYP19A1 substrate recognition makes turinabol an important comparative compound in aromatase biology. The historical GDR doping literature provides extensive long-term pharmacokinetic data not available for most synthetic androgens.
Turinabol urinary metabolite characterisation — 4-chloro-Dianabol metabolites; relevant to research on CYP450 metabolism of 4-chlorinated steroids
Aromatase substrate specificity
CYP19A1 substrate studies confirm 4-chloro substitution prevents aromatisation — mechanistic foundation for turinabol non-oestrogenicity
Research Protocol Design
Aromatase substrate exclusion study
Turinabol vs Dianabol: CYP19A1 (aromatase) in vitro assay using microsomal preparation. Measure oestrogen metabolite production (ELISA or RIA) vs testosterone positive control. Quantifies the 4-chloro substitution effect on aromatase substrate recognition.
GDR historical pharmacokinetics replication
Turinabol oral dosing (1-5mg/kg) in male Sprague-Dawley rats. Serial plasma sampling 0/0.5/1/2/4/8/12/24hr. LC-MS/MS metabolite profiling. Reproduces historical GDR metabolite data in a controlled modern research context.
❓
Frequently Asked Questions
What is the historical significance of turinabol?
Turinabol was synthesised in East Germany (1962) and administered systematically to GDR athletes from the early 1970s through 1989 — the most documented state doping programme in history. The declassified GDR records provide unique long-term pharmacokinetic and pharmacodynamic data for an oral anabolic steroid administered repeatedly over years.
Why does the 4-chloro substitution prevent aromatisation?
CYP19A1 (aromatase) requires the A-ring of the steroid to be accessible for oxidative aromatisation. The 4-chloro substituent on turinabol sterically blocks the CYP19A1 active site at this position — preventing the enzyme from accepting turinabol as a substrate. This is the same mechanism that makes 4-chlorinated testosterone derivatives non-oestrogenic.
Is turinabol the same as Dianabol?
Turinabol is derived from Dianabol (methandrostenolone) with one key modification: the 4-chloro group that prevents aromatisation. Both are 17α-methylated oral androgens with similar anabolic:androgenic ratios, but Dianabol aromatises to potent methyloestradiol while turinabol produces no oestrogenic metabolites.
